Cooley LLP announced today that it advised the underwriters on Receptos, Inc.’s recent IPO. Receptos, now trading on the NASDAQ Global Stock Market under the symbol “RCPT,” is a California-based biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics for immune disorders.
Credit Suisse Securities (USA) LLC, Leerink Swann LLC and BMO Capital Markets acted as joint book-running managers for the offering. Wedbush PacGrow Life Sciences acted as a co-manager.
The Cooley corporate securities team advising the underwriters included partners Tom Coll, Charlie Kim and Sean Clayton and associates Kristin VanderPas, Scott Tanner, Terren O’Connor and Nathan Figler. Regulatory expertise was provided by partners Natasha Leskovsek and Drew Gantt and associate David Sclar. Partner Amy Wood and associate Megan Arthur provided compensation and benefits expertise. Partners Bill Christiansen and Emily Wagner provided intellectual property expertise and partners Susan Cooper Philpot and Bill Morrow provided tax expertise.
Related Posts:
- Cooley Advises Insys Therapeutics on Its IPO
- Cooley Advises Underwriters on HealthEquity’s $146.5 Million IPO
- Cooley Advises Xencor on its Initial Public Offering
- Invitae Completes $117 Million Initial Public Offering
- Dermira Prices its Initial Public Offering
